Atypical antipsychotics as add-on treatment in late-life depression.
BACKGROUND
Second-generation antipsychotics (SGAs) have been used in the augmentation of treatment-resistant depression. However, little is known about their effectiveness, tolerability, and adverse events in the treatment of late-life depression, which were the aim of this study.


METHODS
The retrospective data of patients aged >65 years who had a major depressive episode with inadequate response to antidepressant treatment and had adjuvant SGA treatment were analyzed. The outcome measures were the number of the patients who continued to use SGAs in the fourth and twelfth weeks, adverse events, and changes in symptoms of depression.


RESULTS
Thirty-five patients were screened: 21 (60%) had quetiapine, twelve (34.28%) had aripiprazole, and two (5.71%) had olanzapine adjuvant treatment. The mean age was 72.17±5.02 years, and 65.7% of the patients were women. The mean daily dose was 85.71±47.80 mg for quetiapine, 3.33±1.23 mg for aripiprazole, and 3.75±1.76 mg for olanzapine. The Geriatric Depression Scale scores of all patients were significantly decreased in the fourth week and were significant in the aripiprazole group (P=0.02). Of the 35 patients, 23 (65.7%) patients discontinued the study within 12 weeks. The frequency of adverse events was similar in all SGAs, and the most common were sedation, dizziness, constipation, and orthostatic hypotension with quetiapine, and akathisia and headache because of aripiprazole.


CONCLUSIONS
This study indicates that dropout ratio of patients with SGAs is high, and a subgroup of patients with late-life depression may benefit from SGAs. Effectiveness is significant in aripiprazole, and adverse events of SGAs were not serious but common in elderly patients.
Department of Psychiatry, Mood Disorders, Geriatric Psychiatry Unit, Istanbul Medical School, Istanbul University.
Sibel
S
Cakir
Department of Psychiatry, Marmara University, Istanbul, Turkey.
Zeynep
Z
Senkal
aripiprazole; elderly; olanzapine; quetiapine; treatment resistance
Ann Intern Med. 2007 Jun 5;146(11):775-86
17548409
Arch Gerontol Geriatr. 2011 Jul-Aug;53(1):104-5
20678815
Dialogues Clin Neurosci. 2008;10(4):419-30
19170399
JAMA. 2005 Oct 19;294(15):1934-43
16234500
Am J Geriatr Psychiatry. 2013 Oct;21(10):973-86
23567381
Lancet. 2015 Dec 12;386(10011):2404-12
26423182
Arch Gen Psychiatry. 1997 Oct;54(10):915-22
9337771
Clin Geriatr Med. 2014 Aug;30(3):517-34
25037293
J Clin Psychiatry. 2007;68 Suppl 1:20-7
17286524
Med Hypotheses. 1995 Feb;44(2):111-5
7596303
J Psychiatr Res. 1975 Nov;12(3):189-98
1202204
J Clin Psychiatry. 2009 Feb;70(2):208-13
19210951
Int J Geriatr Psychiatry. 2007 Oct;22(10):986-91
17340654
Lancet. 2013 Nov 9;382(9904):1575-86
23993280
J Clin Psychiatry. 2007 Jun;68(6):826-31
17592905
Depress Anxiety. 2011 Jul;28(7):521-4
21721070
Clin Pract Epidemiol Ment Health. 2007 Nov 26;3:28
18039392
Neuropsychopharmacology. 2008 Apr;33(5):957-70
17637610
Int J Neuropsychopharmacol. 2015 May 25;18(11):pyv060
26012350
J Affect Disord. 2013 Oct;151(1):209-19
23810357
JAMA Psychiatry. 2015 Oct;72 (10 ):1021-8
26288246
Int J Psychiatry Med. 2001;31(3):239-53
11841122
Am J Psychiatry. 2011 Jul;168(7):681-8
21454919
Am J Psychiatry. 2009 May;166(5):583-90
19369318
Acta Psychiatr Scand Suppl. 1987;334:1-100
2887090
Clin Ther. 2000 Sep;22(9):1068-84
11048905
J Psychiatr Res. 1982-1983;17(1):37-49
7183759
J Geriatr Psychiatry Neurol. 2000 Spring;13(1):28-32
10753004